

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	86	(torre buezo jadhav mitch pedregal tercero).in. and ("546" or "548"). clas.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/10/17 14:30
L3	8	l1 and opioid	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/10/17 14:30

=> b reg
 FILE 'REGISTRY' ENTERED AT 13:16:50 ON 17 OCT 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 OCT 2007 HIGHEST RN 950817-67-1
 DICTIONARY FILE UPDATES: 16 OCT 2007 HIGHEST RN 950817-67-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> d que sta 122

L16 2025948 SEA FILE=REGISTRY ABB=ON PLU=ON 46.150.18/RID AND (NC5 OR
 NOC3-C6 OR N2C3-C6)/ES
 L20 STR



VAR G1=O/S/SE
 VAR G2=7/8/9/12/13/16/17/22/21/25/26
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 GGCAT IS MCY UNS AT 3
 DEFAULT ECLEVEL IS LIMITED
 ECOUNT IS E6 C AT 3

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 29

STEREO ATTRIBUTES: NONE
 L22 679 SEA FILE=REGISTRY SUB=L16 SSS FUL L20



100.0% PROCESSED 994793 ITERATIONS
 SEARCH TIME: 00.00.07

679 ANSWERS

=> d que sta 137

L16 2025948 SEA FILE=REGISTRY ABB=ON PLU=ON 46.150.18/RID AND (NC5 OR
 NOC3-C6 OR N2C3-C6)/ES
 L20 STR

N- CH2- Cb- G1- G2
1 2 3 4 5




VAR G1=O/S/SE
VAR G2=7/8/9/12/13/16/17/22/21/25/26
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY UNS AT 3
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS E6 C AT 3

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 29

STEREO ATTRIBUTES: NONE
L22 679 SEA FILE=REGISTRY SUB=L16 SSS FUL L20
L35 STR

N- CH2- Cb- G1- Hy- G2
1 2 3 4 5 6

C=N
@7 8



VAR G1=O/S/SE
VAR G2=7/9
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY UNS AT 3
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS E6 C AT 3

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE
L37 276 SEA FILE=REGISTRY SUB=L22 SSS FUL L35

100.0% PROCESSED 679 ITERATIONS
SEARCH TIME: 00.00.01

276 ANSWERS

=> b hcap
FILE 'HCAPLUS' ENTERED AT 13:17:26 ON 17 OCT 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is

strictly prohibited.

FILE COVERS 1907 - 17 Oct 2007 VOL 147 ISS 17
FILE LAST UPDATED: 16 Oct 2007 (20071016/ED)


New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> => d bib abs hitstr 146

L46 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:638874 HCAPLUS
DN 143:153386
TI A preparation of di(hetero)aryl ethers, useful as opioid receptor antagonists
IN De La Torre, Marta Garcia; Diaz Buezo, Nuria; Jadhav, Prabhakar Kondaji; Mitch, Charles Howard; Pedregal-Tercero, Concepcion
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO2005066164	A1	20050721	2004WO-US39766	20041215
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU2004312312	A1	20050721	2004AU-0312312	20041215
CA---2549089	A1	20050721	2004CA-2549089	20041215
EP---1699783	A1	20060913	2004EP-0812312	20041215
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS			
CN---1894240	A	20070110	CN 2004-80037824	20041215
BR2004017714	A	20070320	2004BR-0017714	20041215
JP2007516284	T	20070621	2006JP-0547016	20041215
US2007112036	A1	20070517	2006US-0581178	20060531
IN2006DN03118	A	20070824	2006IN-DN03118	20060531
MX2006PA07198	A	20060904	2006MX-PA07198	20060622
PRAI 2003EP-0380303	A	20031222		
2004US-539748P	P	20040128		
2004WO-US39766	W	20041215		
OS CASREACT 143:153386; MARPAT 143:153386				
GI				



AB The invention relates to a preparation of di(hetero)aryl ethers, useful as opioid receptor antagonists. The invention compds. are useful for the


treatment, prevention or amelioration of obesity and related diseases. For instance, phenoxynicotinamide derivative I [GTP- γ -S binding assay, K_i (nM): μ - 43.43, κ - 117.09, δ - 269.06] was prepared via addition of hydroxylamine to phenoxynicotinonitrile derivative II with a yield of 63%.

IT 859505-27-4P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of di(hetero)aryl ethers useful as opioid receptor antagonists)

RN 859505-27-4 HCAPLUS

CN 3-Pyridinecarboximidic acid, 6-[4-[[[3-methylbutyl)amino)methyl]phenoxy]-, ethyl ester (CA INDEX NAME)



IT 859505-28-5P 859505-29-6P 859505-30-9P

859505-31-0P 859505-33-2P 859505-34-3P

859505-35-4P 859505-36-5P 859505-37-6P

859505-39-8P 859505-47-8P 859505-48-9P


859505-49-0P 859505-50-3P 859505-52-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of di(hetero)aryl ethers useful as opioid receptor antagonists)


RN 859505-28-5 HCAPLUS

CN 3-Pyridinecarboximidamide, N-hydroxy-6-[4-[[[3-methylbutyl)amino)methyl]phenoxy]- (CA INDEX NAME)




RN 859505-29-6 HCAPLUS

CN 3-Pyridinecarboximidamide, 6-[4-[[[3-methylbutyl)amino)methyl]phenoxy]- (CA INDEX NAME)




RN 859505-30-9 HCAPLUS

CN Benzenemethanamine, 4-[[[5-(4,5-dihydro-1H-imidazol-2-yl)-2-pyridinyl]oxy]-N-(3-methylbutyl)- (CA INDEX NAME)




RN 859505-31-0 HCAPLUS

CN 2-Thiopheneethanamine, N-[[[4-[[[5-(4,5-dihydro-1H-imidazol-2-yl)-2-pyridinyl]oxy]phenyl]methyl]- (CA INDEX NAME)




RN 859505-33-2 HCAPLUS

CN Benzenemethanamine, N-(3-methylbutyl)-4-[[5-(4,5,6,7-tetrahydro-1H-1,3-diazepin-2-yl)-2-pyridinyl]oxy]- (CA INDEX NAME)




RN 859505-34-3 HCAPLUS

CN Benzenemethanamine, N-(3-methylbutyl)-4-[[5-(1,4,5,6-tetrahydro-2-pyrimidinyl)-2-pyridinyl]oxy]- (CA INDEX NAME)




RN 859505-35-4 HCAPLUS

CN 3-Pyridinecarboximidamide, N-cyano-6-[4-[(3-methylbutyl)amino]methyl]phenoxy]- (CA INDEX NAME)




RN 859505-36-5 HCAPLUS

CN Benzenemethanamine, N-(3-methylbutyl)-4-[[5-(1H-tetrazol-5-yl)-2-pyridinyl]oxy]- (9CI) (CA INDEX NAME)




RN 859505-37-6 HCAPLUS

CN Benzenemethanamine, 4-[[5-(1H-imidazol-2-yl)-2-pyridinyl]oxy]-N-(3-methylbutyl)- (CA INDEX NAME)




RN 859505-39-8 HCAPLUS


CN 1,2-Benzisoxazol-3-amine, 6-[4-[(3-methylbutyl)amino]methyl]phenoxy]- (CA INDEX NAME)



RN 859505-47-8 HCAPLUS


CN 1,2-Benzisoxazol-3-amine, 6-[4-[[[(3,3-dimethylbutyl)amino]methyl]phenoxy]-
(CA INDEX NAME)

RN 859505-48-9 HCAPLUS


CN 1,2-Benzisoxazol-3-amine, 6-[4-[[[2-(4-fluorophenyl)ethyl]amino]methyl]phe
noxy]- (CA INDEX NAME)

RN 859505-49-0 HCAPLUS


CN 1,2-Benzisoxazol-3-amine, 6-[4-[[[2-(tetrahydro-2H-pyran-4-yl)ethyl]amino]methyl]phenoxy]- (CA INDEX NAME)



RN 859505-50-3 HCAPLUS

CN 1H-Indazol-3-amine, 6-[4-[[[(3-methylbutyl)amino]methyl]phenoxy]- (CA
INDEX NAME)

RN 859505-52-5 HCAPLUS


CN 3-Pyridinecarboxylic acid, 6-[4-[[[(3-methylbutyl)amino]methyl]phenoxy]-
(CA INDEX NAME)

IT 859505-38-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of di(hetero)aryl ethers useful as opioid receptor antagonists)

RN 859505-38-7 HCAPLUS

CN 3-Pyridinecarboximidamide, N-(2,2-dimethoxyethyl)-6-[4-[[[3-methylbutyl)amino]methyl]phenoxy]- (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib abs hitstr 145

L45 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:267241 HCAPLUS

DN 140:303538

TI Preparation of [[(aminoalkyl)aryl]oxy]nicotinamides and analogs as opioid
receptor antagonist for treatment of obesity and related conditions

IN Blanco-Pillado, Maria-Jesus; Chappell, Mark Donald; Garcia De la Torre,
Marta; Diaz Buezo, Nuria; Fritz, James Erwin; Holloway, William Glen;
Matt, James Edward, Jr.; Mitch, Charles Howard; Pedregal-Tercero,
Concepcion; Quimby, Steven James; Siegel, Miles Goodman; Smith, Dana Rae;
Stucky, Russell Dean; Takeuchi, Kumiko; Thomas, Elizabeth Marie; Wolfe,
Chad Nolan

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 559 pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO2004026305	A1	20040401	2003WO-US26300	20030917 <--
WO2004026305	A9	20040513		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA---2499690	A1	20040401	2003CA-2499690	20030917 <--
AU2003269980	A1	20040408	2003AU-0269980	20030917 <--
BR2003014308	A	20050705	2003BR-0014308	20030917 <--
EP---1562595	A1	20050817	2003EP-0751877	20030917 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
CN---1681498	A	20051012	2003CN-0822241	20030917 <--
JP2006511474	T	20060406	2004JP-0537682	20030917 <--
US2006217372	A1	20060928	2005US-0526960	20050303 <--
MX2005PA03093	A	20050713	2005MX-PA03093	20050318 <--
IN2005KN00457	A	20060303	2005IN-KN00457	20050318 <--
NO2005001871	A	20050418	2005NO-0001871	20050418 <--
PRAI 2002US-412158P	P	20020919	<--	
2003WO-US26300	W	20030917	<--	
OS MARPAT 140:303538				
GI				




AB Title diaryl ethers I [wherein X1-X10 = independently C, CH, or N; provided that each of rings A or B has no more than 2 N atoms; E = O or NH; R1 and R2 = independently H or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, (alkyl)aryl, (aryl)heterocyclyl, (cyclo)alkylheterocyclyl, (cyclo)alkanoylalkyl, aroylalkyl, aryloxyalkyl, benzhydryl, bicyclyl(alkyl), benzoyl(alkyl), alkoxyalkyl, alkoxy carbonyl, (aryl)alkylsulfonyl, heterocyclylalkylsulfonyl, cycloalkylalkyl, carboxyalkyl, carbamoylalkyl, etc.; R3 and R3' = independently H, alkyl, alkenyl, alkynyl, (alkyl)aryl, or alkylcycloalkyl; R4 and R5 = independently H, (halo)alkyl, alkenyl, alkynyl, alkoxy(halo)alkyl, thioalkyl, halo, aryl(alkyl), alkanoyl, alkoxy carbonyl, aminoalkyl, cycloalkylalkyl, etc.; R6 and R7 = independently H, (cyclo)alkyl, alkenyl, alkynyl, alkanoyl, OH, alkoxy, (aryl)alkylsulfonyl, heterocyclylalkylsulfonyl, aryl(alkyl), carbamoyl(alkyl), etc.; m = 1-3; n = 0-3; p = 0-3; or pharmaceutically acceptable salts, solvates, enantiomers, racemates, diastereomers, or mixts. thereof] were prepared as μ -, κ -, and δ -opioid receptor antagonists. For example, reductive amination of 6-(2-fluoro-4-formylphenoxy)nicotinamide and 3-methylbutylamine provided II (99%). The latter inhibited ex vivo binding of [3H]-diprenorphine in rat striatum/nucleus accumbens by >65% at a concentration of 7 mg/kg. In an acute feeding rat obesity assay, II suppressed opioid receptors at a dose of 0.3 μ g/kg. In addition, diet-induced obese rats achieved an energy balance (caloric intake minus utilization) of -81 kcal/kg/day upon administration of 0.3 mg/kg p.o. of II in an indirect calorimetry assay. Thus, I and their pharmaceutical compns. are useful for the treatment, prevention, or amelioration of obesity and related diseases.

IT 676496-11-0P, 6-[2-Methoxy-4-[[[2-(4-methylcyclohexyl)ethyl]amino]methyl]phenoxy]nicotinamide 676496-29-0P, 4-[(6-Carbamoylpyridin-3-yl)oxy]benzyl] (phenethyl) carbamic acid tert-butyl ester 676496-49-4P, 5-[4-[(3-Methylbutylamino)methyl]phenoxy]pyridine-2-carboxamide 676497-19-1P, 6-[2-Methoxy-4-[(4-methylpentylamino)methyl]phenoxy]nicotinamide 676497-21-5P, 6-[2-Methoxy-4-[[[2-(p-tolyl)ethyl]amino]methyl]phenoxy]nicotinamide 676497-85-1P 676501-30-7P, 5-[2-Methoxy-4-[[[2-(tetrahydropyran-4-yl)ethyl]amino]methyl]phenoxy]pyridine-2-carboxamide 676501-43-2P, 6-[4-[(Phenethylamino)methyl]phenoxy]nicotinic acid ethyl ester 676501-44-3P, 4-[(5-Ethylcarbamoylpyridin-2-yl)oxy]benzyl] (phenethyl) carbamic acid tert-butyl ester 676501-45-4P, 6-[4-[[[tert-Butoxycarbonyl] (phenethyl)amino]methyl]phenoxy]nicotinic acid 676501-50-1P, 6-[4-[(3-Methylbutylamino)methyl]phenoxy]nicotinic acid ethyl ester 676501-51-2P, 6-[4-[[[tert-Butoxycarbonyl] (phenethyl)amino]methyl]phenoxy]nicotinic acid ethyl ester 676501-52-3P, 6-[4-[[[tert-Butoxycarbonyl] (3-methylbutyl)amino]methyl]phenoxy]nicotinic acid ethyl ester 676501-53-4P, 6-[4-[[[tert-Butoxycarbonyl] (3-methylbutyl)amino]methyl]phenoxy]nicotinic acid 676501-54-5P, 4-[[[5-(Isopropylcarbamoyl)pyridin-2-yl]oxy]benzyl] (phenethyl) carbamic acid tert-butyl ester 676501-55-6P, N-(3-Methylbutyl)-N-[4-[(5-methylcarbamoylpyridin-2-yl)oxy]benzyl] carbamic acid tert-butyl ester 676501-56-7P, N-[4-[(5-Ethylcarbamoylpyridin-2-yl)oxy]benzyl] (3-methylbutyl) carbamic acid tert-butyl ester 676501-57-8P, 4-[[[5-(Isopropylcarbamoyl)pyridin-2-yl]oxy]benzyl] (3-methylbutyl) carbamic acid tert-butyl ester
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of (aryloxy)nicotinamides and analogs as opioid receptor antagonist for treatment of obesity and related conditions)


RN 676496-11-0 HCAPLUS

CN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[[[2-(4-methylcyclohexyl)ethyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676496-29-0 HCAPLUS

CN Carbamic acid, [[4-[[6-(aminocarbonyl)-3-pyridinyl]oxy]phenyl]methyl](2-phenylethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 676496-49-4 HCAPLUS

CN 2-Pyridinecarboxamide, 5-[4-[[[3-methylbutyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676497-19-1 HCAPLUS

CN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[[[4-methylpentyl]amino]methyl]phenoxy]- (CA INDEX NAME)



RN 676497-21-5 HCAPLUS


CN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[[[2-(4-methylphenyl)ethyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676497-85-1 HCAPLUS

CN Carbamic acid, [[4-[[5-(aminocarbonyl)-2-pyridinyl]oxy]-3-


chlorophenyl)methyl](3,3-dimethylbutyl)-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)




RN 676501-30-7 HCAPLUS
CN 2-Pyridinecarboxamide, 5-[2-methoxy-4-[[[2-(tetrahydro-2H-pyran-4-yl)ethyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676501-43-2 HCAPLUS
CN 3-Pyridinecarboxylic acid, 6-[4-[[[2-(phenylethyl)amino]methyl]phenoxy]-, ethyl ester (CA INDEX NAME)




RN 676501-44-3 HCAPLUS
CN Carbamic acid, [[4-[[5-[(ethylamino)carbonyl]-2-pyridinyl]oxy]phenyl]methyl](2-phenylethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 676501-45-4 HCAPLUS
CN 3-Pyridinecarboxylic acid, 6-[4-[[[1,1-dimethylethoxy]carbonyl](2-phenylethyl)amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676501-50-1 HCAPLUS
CN 3-Pyridinecarboxylic acid, 6-[4-[[[3-methylbutyl]amino]methyl]phenoxy]-, ethyl ester (CA INDEX NAME)




RN 676501-51-2 HCAPLUS

CN 3-Pyridinecarboxylic acid, 6-[4-[[[(1,1-dimethylethoxy)carbonyl](2-phenylethyl)amino]methyl]phenoxy]-, ethyl ester (CA INDEX NAME)




RN 676501-52-3 HCAPLUS

CN 3-Pyridinecarboxylic acid, 6-[4-[[[(1,1-dimethylethoxy)carbonyl](3-methylbutyl)amino]methyl]phenoxy]-, ethyl ester (CA INDEX NAME)




RN 676501-53-4 HCAPLUS

CN 3-Pyridinecarboxylic acid, 6-[4-[[[(1,1-dimethylethoxy)carbonyl](3-methylbutyl)amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676501-54-5 HCAPLUS

CN Carbamic acid, [[4-[[5-[[[(1-methylethyl)amino]carbonyl]-2-pyridinyl]oxy]phenyl]methyl](2-phenylethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 676501-55-6 HCAPLUS

CN Carbamic acid, [[4-[[5-[(methylamino)carbonyl]-2-pyridinyl]oxy]phenyl]methyl](3-methylbutyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 676501-56-7 HCAPLUS

CN Carbamic acid, {[4-[[5-[(ethylamino)carbonyl]-2-pyridinyl]oxy]phenyl]methyl}-(3-methylbutyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 676501-57-8 HCAPLUS


CN Carbamic acid, (3-methylbutyl){[4-[[[2-(1-methylethyl)amino]carbonyl]-2-pyridinyl]oxy]phenyl]methyl}-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 676494-38-5P, 6-[2-Methyl-4-[(3-methylbutylamino)methyl]phenoxy]nicotinamide 676494-39-6P, 6-[2-Fluoro-4-[[[3-methylbutyl]amino]methyl]phenoxy]nicotinamide 676497-13-5P, 6-[2-Methoxy-4-[[[2-(tetrahydropyran-4-yl)ethyl]amino]methyl]phenoxy]nicotinamide 676497-16-8P, 6-[4-[[[2-(4-Fluorophenyl)ethyl]amino]methyl]-2-methoxyphenoxy]nicotinamide 676497-17-9P, 6-[4-[[[2-(2-Fluorophenyl)ethyl]amino]methyl]-2-methoxyphenoxy]nicotinamide 676501-07-8P, 5-[4-[[[4,4-Dimethylpentyl]amino]methyl]-2-fluorophenoxy]pyridine-2-carboxamide 676501-25-0P, 6-[2-Fluoro-4-[[[2-(tetrahydropyran-4-yl)ethyl]amino]methyl]phenoxy]nicotinamide
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (opioid receptor antagonist; preparation of (aryloxy)nicotinamides and analogs as opioid receptor antagonist for treatment of obesity and related conditions)


RN 676494-38-5 HCAPLUS

CN 3-Pyridinecarboxamide, 6-[2-methyl-4-[[[3-methylbutyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676494-39-6 HCAPLUS


CN 3-Pyridinecarboxamide, 6-[2-fluoro-4-[[[3-methylbutyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676497-13-5 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[[[2-(tetrahydro-2H-pyran-4-yl)ethyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676497-16-8 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[[2-(4-fluorophenyl)ethyl]amino]methyl]-2-methoxyphenoxy]- (CA INDEX NAME)




RN 676497-17-9 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[[2-(2-fluorophenyl)ethyl]amino]methyl]-2-methoxyphenoxy]- (CA INDEX NAME)



RN 676501-07-8 HCAPLUS
 CN 2-Pyridinecarboxamide, 5-[4-[[[2-(4,4-dimethylpentyl)amino]methyl]-2-fluorophenoxy]- (CA INDEX NAME)



RN 676501-25-0 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[2-fluoro-4-[[[2-(tetrahydro-2H-pyran-4-yl)ethyl]amino]methyl]phenoxy]- (CA INDEX NAME)



IT 676494-28-3P, 6-[2-Methyl-4-[(phenethylamino)methyl]phenoxy]nicotinamide 676494-30-7P, 6-[2-Fluoro-4-[(phenethylamino)methyl]phenoxy]nicotinamide 676494-32-9P, 6-[2-Ethoxy-4-[(phenethylamino)methyl]phenoxy]nicotinamide 676494-34-1P, 6-[2-Chloro-4-[(phenethylamino)methyl]phenoxy]nicotinamide 676494-36-3P, 6-[3-Chloro-4-[(phenethylamino)methyl]phenoxy]nicotinamide 676494-40-9P, 6-[2-Chloro-4-[(3-methylbutylamino)methyl]phenoxy]nicotinamide 676494-41-0P, 6-[2-Ethoxy-4-[(3-methylbutylamino)methyl]phenoxy]nicotinamide 676494-42-1P, 6-[4-[(2-Cyclopentylethylamino)methyl]-2-methylphenoxy]nicotinamide 676494-43-2P, 6-[4-[(2-Cyclopentylethyl)amino)methyl]-2-fluorophenoxy]nicotinamide 676494-44-3P, 6-[2-Chloro-4-[(2-Cyclopentylethyl)amino)methyl]phenoxy]nicotinamide 676494-45-4P, 6-[4-[(2-Cyclopentylethylamino)methyl]-2-ethoxyphenoxy]nicotinamide 676494-46-5P, 6-[2-Methyl-4-[[[2-(thiophen-2-yl)ethyl]amino)methyl]phenoxy]nicotinamide 676494-47-6P, 6-[4-[[[2-(3-Fluorophenyl)ethyl]amino)methyl]-2-methylphenoxy]nicotinamide 676494-48-7P, 6-[2-Methyl-4-[[[2-(o-tolyl)ethyl]amino)methyl]phenoxy]nicotinamide 676494-50-1P, 6-[4-[[[2-(3-Chlorophenyl)ethyl]amino)methyl]-2-methylphenoxy]nicotinamide 676494-51-2P, 6-[4-[(Butylamino)methyl]-2-methylphenoxy]nicotinamide 676494-53-4P, 6-[2-Methyl-4-[(methylphenethylamino)methyl]phenoxy]nicotinamide 676494-69-2P, 6-[4-[(Benzylamino)methyl]phenoxy]nicotinamide 676494-71-6P, 6-[4-[(Allylamino)methyl]phenoxy]nicotinamide 676494-72-7P, 6-[4-[(4-Methoxybenzylamino)methyl]phenoxy]nicotinamide 676494-73-8P, 6-[4-[(3-Trifluoromethylbenzylamino)methyl]phenoxy]nicotinamide 676494-74-9P, 6-[4-[[[2-(Thiophen-2-yl)ethyl]amino)methyl]phenoxy]nicotinamide 676494-75-0P, 6-[4-[(3-Fluorobenzylamino)methyl]phenoxy]nicotinamide 676494-76-1P, 6-[4-[[[2-(Furan-2-ylmethyl)amino)methyl]phenoxy]nicotinamide 676494-77-2P, 6-[4-[[[2-(3-Fluorophenyl)ethyl]amino)methyl]phenoxy]nicotinamide 676494-78-3P, 6-[4-[[[4-Trifluoromethoxybenzyl]amino)methyl]phenoxy]nicotinamide 676494-79-4P, 6-[4-[(Phenethylamino)methyl]phenoxy]nicotinamide 676494-80-7P, 6-[4-[[[2-(3-Chlorophenyl)ethyl]amino)methyl]phenoxy]nicotinamide 676494-81-8P, 6-[4-[[[2-(4-Sulfamoylphenyl)ethyl]amino)methyl]phenoxy]nicotinamide 676494-82-9P, 6-[4-[(3-Phenylpropylamino)methyl]phenoxy]nicotinamide 676494-83-0P, 6-[4-[[[3,3-Diphenylpropylamino)methyl]phenoxy]nicotinamide 676494-84-1P, 6-[4-[[[3,3-Dimethylbutylamino)methyl]phenoxy]nicotinamide 676494-85-2P, 6-[4-[[[2-(2-Methoxyphenyl)ethyl]amino)methyl]phenoxy]nicotinamide 676494-86-3P, 6-[4-[[[2-(Phenylaminoethylamino)methyl]phenoxy]nicotinamide 676494-87-4P, 6-[4-[[[2-(Phenylpropylamino)methyl]phenoxy]nicotinamide 676494-88-5P, 6-[4-[[[2-(Pyridin-2-yl)ethyl]amino)methyl]phenoxy]nicotinamide 676494-89-6P, 6-[4-[[[2-(2-Chlorophenyl)ethyl]amino)methyl]phenoxy]nicotinamide 676494-90-9P, 6-[4-[[[2-(Pyridin-3-yl)ethyl]amino)methyl]phenoxy]nicotinamide 676494-91-0P, 6-[4-[[[2,2-Diphenylethylamino)methyl]phenoxy]nicotinamide 676494-92-1P, 6-[4-[[[3-Methylbutylamino)methyl]phenoxy]nicotinamide 676494-93-2P, 6-[4-[[[2-Cyclohexylethylamino)methyl]phenoxy]nicotinamide 676494-94-3P, 6-[4-[[[2-Methylsulfanylethyl]amino)methyl]phenoxy]nicotinamide 676494-95-4P, 6-[4-[[[6-Hydroxyhexylamino)methyl]phenoxy]nicotinamide 676494-96-5P, 6-[4-[[[2-Dimethylaminoethylamino)methyl]phenoxy]nicotinamide 676494-97-6P, 6-[4-[[[Decylamino)methyl]phenoxy]nicotinamide 676494-98-7P, 6-[4-[[[2-Ethylhexylamino)methyl]phenoxy]nicotinamide 676494-99-8P, 6-[4-[[[2-(Tetrahydrofuran-2-ylmethyl)amino)methyl]phenoxy]nicotinamide 676495-00-4P, 6-[4-[[[2-(Pyrrolidin-1-yl)ethyl]amino)methyl]phenoxy]nicotinamide 676495-01-5P, 6-[4-[[[2-(1-Methylpyrrolidin-2-yl)ethyl]amino)methyl]phenoxy]nicotinamide 676495-02-6P, 6-[4-[[[2-(1H-Imidazol-4-yl)ethyl]amino)methyl]phenoxy]nicotinamide 676495-03-7P,

6-[4-[[[3-(2-Methylpiperidin-1-yl)propyl]amino]methyl]phenoxy]nicotinamide
676495-04-8P, 6-[4-[(2-Diisopropylaminoethylamino)methyl]phenoxy]n
icotinamide 676495-05-9P, 6-[4-[(2-Cyclohex-1-
enylethylamino)methyl]phenoxy]nicotinamide 676495-06-0P,
6-[4-[(Pentylamino)methyl]phenoxy]nicotinamide 676495-26-4P,
6-[4-[[[2-(3,4-Dichlorophenyl)ethyl]amino]methyl]phenoxy]nicotinamide
676495-27-5P, 6-[4-[[[2-(2-Ethoxyphenyl)ethyl]amino]methyl]phenoxy
]nicotinamide 676495-28-6P, 6-[4-[[[2-(o-
Tolyl)ethyl]amino]methyl]phenoxy]nicotinamide 676495-29-7P,
6-[4-[[[2-(2-Phenoxyphenyl)ethyl]amino]methyl]phenoxy]nicotinamide
676495-39-9P, 6-[4-[(2-Phenylethylamino)methyl]-2,5-
dimethylphenoxy]nicotinamide 676495-41-3P, 6-[4-[[[2-(Thiophen-2-
yl)ethyl]amino]methyl]-2-ethoxyphenoxy]nicotinamide 676495-42-4P
, 6-[4-[(3-Methylbutylamino)methyl]-2-ethoxyphenoxy]nicotinamide
methanesulfonate 676495-43-5P, 6-[4-[(Butylamino)methyl]-2-
ethoxyphenoxy]nicotinamide 676495-44-6P, 6-[4-[(2-
Cyclopentylethylamino)methyl]-2-ethoxyphenoxy]nicotinamide
methanesulfonate 676495-67-3P, (R)-6-[4-[(1-Benzylpyrrolidin-3-
ylamino)methyl]phenoxy]nicotinamide 676496-12-1P,
6-[2-Methoxy-4-[[[2-(4-methylcyclohexyl)ethyl]amino]methyl]phenoxy]nicotin
amide methanesulfonate 676496-22-3P, 6-[4-
[[[Phenethylamino)methyl]phenoxy]nicotinamide 676496-28-9P,
5-[4-[[[Phenethylamino)methyl]phenoxy]pyridine-2-carboxamide
676496-41-6P, N-Methyl-6-[4-[[[phenethylamino)methyl]phenoxy]nicoti
namidine 676496-45-0P, 5-[4-[[[2-(4-
Fluorophenyl)ethyl]amino]methyl]phenoxy]pyridine-2-carboxamide
676496-50-7P, 5-[4-[[[3-Methylbutylamino)methyl]phenoxy]pyridine-2-
carboxamide methanesulfonate 676496-52-9P, 5-[2-Methyl-4-[[[3-
methylbutylamino)methyl]phenoxy]pyridine-2-carboxamide methanesulfonate
676496-55-2P, 5-[2-Methoxy-4-[[[3-methylbutylamino)methyl]phenoxy]p
yridine-2-carboxamide methanesulfonate 676496-58-5P,
5-[4-[[[2-(3-Trifluoromethylphenyl)ethyl]amino]methyl]phenoxy]pyridine-2-
carboxamide methanesulfonate 676496-60-9P, 5-[4-[[[2-(Thiophen-2-
yl)ethyl]amino]methyl]phenoxy]pyridine-2-carboxamide methanesulfonate
676496-62-1P, 5-[2-Methyl-4-[[[2-(thiophen-2-
yl)ethyl]amino]methyl]phenoxy]pyridine-2-carboxamide methanesulfonate
676496-64-3P, 5-[2-Methoxy-4-[[[2-(thiophen-2-
yl)ethyl]amino]methyl]phenoxy]pyridine-2-carboxamide methanesulfonate
676496-68-7P, 5-[4-[[[2-(Cyclopentylethylamino)methyl]-2-
methylphenoxy]pyridine-2-carboxamide methanesulfonate 676496-70-1P
, 5-[4-[[[2-(Cyclopentylethylamino)methyl]-2-methoxyphenoxy]pyridine-2-
carboxamide methanesulfonate 676496-72-3P, 5-[4-
[[[2-(Benzo[b]thiophen-3-yl)methyl]amino]methyl]phenoxy]pyridine-2-
carboxamide methanesulfonate 676496-74-5P, 5-[4-[[[2-(4-
Methoxyphenyl)ethyl]amino]methyl]phenoxy]pyridine-2-carboxamide
methanesulfonate 676496-76-7P, 5-[4-[[[2-(3-
Fluorophenyl)ethyl]amino]methyl]phenoxy]pyridine-2-carboxamide
methanesulfonate 676496-78-9P, 5-[4-[[[2-(2-
Fluorophenyl)ethyl]amino]methyl]phenoxy]pyridine-2-carboxamide
methanesulfonate 676496-80-3P, 5-[2-Fluoro-4-[[[3-
methylbutylamino)methyl]phenoxy]pyridine-2-carboxamide methanesulfonate
676496-88-1P, 5-[2-Fluoro-4-[[[pentylamino)methyl]phenoxy]pyridine-
2-carboxamide 676496-89-2P, 5-[2-Fluoro-4-[[[2-(thiophen-2-
yl)ethyl]amino]methyl]phenoxy]pyridine-2-carboxamide 676496-90-5P
, 5-[2-Fluoro-4-[[[2-(pyridin-3-yl)ethyl]amino]methyl]phenoxy]pyridine-2-
carboxamide 676496-91-6P, 5-[2-Fluoro-4-[[[2-(m-
tolyl)ethyl]amino]methyl]phenoxy]pyridine-2-carboxamide
676496-92-7P, 5-[2-Fluoro-4-[[[2-(4-fluorophenyl)ethyl]amino]methy
l]phenoxy]pyridine-2-carboxamide 676496-93-8P,
5-[2-Chloro-4-[[[3-methylbutylamino)methyl]phenoxy]pyridine-2-carboxamide
676496-96-1P, 5-[2-Chloro-4-[[[pentylamino)methyl]phenoxy]pyridine-
2-carboxamide 676496-97-2P, 5-[2-Chloro-4-[[[2-(thiophen-2-
yl)ethyl]amino]methyl]phenoxy]pyridine-2-carboxamide 676496-98-3P
, 5-[2-Chloro-4-[[[2-(pyridin-3-yl)ethyl]amino]methyl]phenoxy]pyridine-2-
carboxamide 676496-99-4P, 6-[2-Methoxy-4-[[[3-
methylbutylamino)methyl]phenoxy]nicotinamide 676497-01-1P,
5-[2-Fluoro-4-[[[2-(tetrahydropyran-4-yl)ethyl]amino]methyl]phenoxy]pyridi
ne-2-carboxamide 676497-02-2P, 5-[2-Fluoro-4-[[[2-(o-
tolyl)ethyl]amino]methyl]phenoxy]pyridine-2-carboxamide
676497-03-3P, 5-[4-[[[2-(Naphthalen-2-
yl)ethyl]amino]methyl]phenoxy]pyridine-2-carboxamide 676497-04-4P
, 5-[4-[[[2-(Naphthalen-1-yl)ethyl]amino]methyl]phenoxy]pyridine-2-
carboxamide 676497-05-5P, 5-[4-[[[2-(Benzo[b]thiophen-3-
yl)ethyl]amino]methyl]phenoxy]pyridine-2-carboxamide 676497-06-6P
, 6-[2-Methoxy-4-[[[pentylamino)methyl]phenoxy]nicotinamide
676497-07-7P, 6-[2-Methoxy-4-[[[2-(thiophen-2-


yl)ethyl]amino)methyl]phenoxy]nicotinamide 676497-08-8P,
 6-[2-Methoxy-4-[[[2-(o-tolyl)ethyl]amino)methyl]phenoxy]nicotinamide
 676497-09-9P, 6-[2-Methoxy-4-[[[2-(m-tolyl)ethyl]amino)methyl]phen
 oxy]nicotinamide 676497-10-2P, 6-[4-[[[3,3-
 Dimethylbutylamino)methyl]-2-methoxyphenoxy]nicotinamide
 676497-11-3P, 6-[2-Methoxy-4-[[[2-(pyridin-3-
 yl)ethyl]amino)methyl]phenoxy]nicotinamide 676497-12-4P,
 6-[4-[[[Butylamino)methyl]-2-methoxyphenoxy]nicotinamide
 676497-14-6P, 6-[2-Methoxy-4-[[[2-(morpholin-4-
 yl)ethyl]amino)methyl]phenoxy]nicotinamide 676497-15-7P,
 6-[4-[[[2-Ethylbutyl]amino)methyl]-2-methoxyphenoxy]nicotinamide
 676497-18-0P, 6-[4-[[[Hexylamino)methyl]-2-
 methoxyphenoxy]nicotinamide 676497-20-4P, 6-[2-Methoxy-4-[[[4-
 methylpentylamino)methyl]phenoxy]nicotinamide methanesulfonate
 676497-22-6P, 6-[2-Methoxy-4-[[[2-(p-tolyl)ethyl]amino)methyl]phen
 oxy]nicotinamide methanesulfonate 676497-30-6P,
 6-[2-Methoxy-4-[[[2-(tetrahydropyran-4-yl)ethyl]amino)methyl]phenoxy]nicot
 inamide methanesulfonate 676497-67-9P, 6-[2-Fluoro-4-[[[3-
 methylbutyl](pentyl)amino)methyl]phenoxy]nicotinamide 676497-68-0P
 , 6-[2-Fluoro-4-[[[N-(3-methylbutyl)-N-propylamino)methyl]phenoxy]nicotinam
 ide 676497-69-1P, 6-[4-[[[Bis(3-methylbutyl)amino)methyl]-2-
 fluorophenoxy]nicotinamide 676497-86-2P, 6-[2-Chloro-4-[[[3,3-
 dimethylbutylamino)methyl]phenoxy]nicotinamide 676497-87-3P,
 6-[2-Chloro-4-[[[2-(thiophen-2-yl)ethyl]amino)methyl]phenoxy]nicotinamide
 676499-89-1P, 6-[4-[[[3-Methylbutyl](cyclopropylmethyl)amino)methyl
]]-2-fluorophenoxy]nicotinamide 676499-90-4P,
 6-[4-[[[3-Methylbutyl](cyclohexylmethyl)amino)methyl]-2-
 fluorophenoxy]nicotinamide 676499-91-5P, 6-[4-[[[2-(3-
 Pyridyl)ethyl](ethyl)amino)methyl]-2-fluorophenoxy]nicotinamide
 676499-92-6P, 6-[4-[[[Cyclopropylmethyl]amino)methyl]-2-
 fluorophenoxy]nicotinamide 676499-93-7P, 6-[4-
 [[[(Cyclohexylmethyl)amino)methyl]-2-fluorophenoxy]nicotinamide
 676499-94-8P, 6-[4-[[[Cycloheptylamino)methyl]-2-
 fluorophenoxy]nicotinamide 676499-95-9P, 6-[4-
 [[[(Cyclooctylamino)methyl]-2-fluorophenoxy]nicotinamide
 676499-96-0P, 6-[4-[[[tert-Butylamino)methyl]-2-
 fluorophenoxy]nicotinamide 676499-97-1P, 6-[4-[[[2-
 Furylmethylamino)methyl]-2-fluorophenoxy]nicotinamide 676499-98-2P
 676499-99-3P 676500-00-8P, 6-[4-[[[Ethylamino)methyl]-2-
 fluorophenoxy]nicotinamide 676500-01-9P, 6-[2-Fluoro-4-
 [[[propylamino)methyl]phenoxy]nicotinamide 676500-02-0P,
 6-[2-Fluoro-4-[[[hexylamino)methyl]phenoxy]nicotinamide
 676500-03-1P, 6-[2-Fluoro-4-[[[isobutylamino)methyl]phenoxy]nicotin
 amide 676500-25-7P, 6-[4-[[[3-Methylbutyl]amino)methyl]phenoxy]n
 icotinamide hydrochloride 676500-38-2P, 6-[2,3-Difluoro-4-
 [[[pentylamino)methyl]phenoxy]nicotinamide 676500-42-8P,
 6-[4-[[[3,3-Dimethylbutylamino)methyl]-2-fluoro-6-
 methoxyphenoxy]nicotinamide 676500-45-1P, 6-[4-[[[3,3-
 Dimethylbutylamino)methyl]-2,6-difluorophenoxy]nicotinamide
 676500-48-4P, 6-[2,6-Difluoro-4-[[[3-methylbutylamino)methyl]phenox
 y]nicotinamide 676500-49-5P, 6-[2,3,6-Trifluoro-4-[[[3-
 methylbutylamino)methyl]phenoxy]nicotinamide 676500-53-1P,
 6-[3-[[[2-Cyclohexylethylamino)methyl]-2-methylphenoxy]nicotinamide
 676500-64-4P, 6-[4-[[[2-(2,4-Difluorophenyl)ethyl]amino)methyl]-2-
 methoxyphenoxy]nicotinamide methanesulfonate 676500-73-5P,
 6-[2-Methoxy-4-[[[propylamino)methyl]phenoxy]nicotinamide methanesulfonate
 676500-75-7P, 6-[4-[[[Isobutylamino)methyl]-2-
 methoxyphenoxy]nicotinamide methanesulfonate 676500-77-9P,
 6-[4-[[[2,2-Dimethylpropylamino)methyl]-2-methoxyphenoxy]nicotinamide
 methanesulfonate 676500-79-1P, 6-[2-Methoxy-4-[[[tetrahydropyran-
 4-ylmethyl]amino)methyl]phenoxy]nicotinamide methanesulfonate
 676500-81-5P, 6-[4-[[[Heptylamino)methyl]-2-
 methoxyphenoxy]nicotinamide methanesulfonate 676500-83-7P,
 6-[2-Methoxy-4-[[[2-(pyridin-4-yl)ethyl]amino)methyl]phenoxy]nicotinamide
 methanesulfonate 676500-85-9P, 6-[2-Methoxy-4-[[[3-
 methoxypropylamino)methyl]phenoxy]nicotinamide methanesulfonate
 676500-87-1P, 6-[4-[[[3-Ethoxypropylamino)methyl]-2-
 methoxyphenoxy]nicotinamide methanesulfonate 676500-89-3P,
 6-[4-[[[3-Isopropoxypropylamino)methyl]-2-methoxyphenoxy]nicotinamide
 methanesulfonate 676500-91-7P, 6-[4-[[[2-
 Isopropoxyethylamino)methyl]-2-methoxyphenoxy]nicotinamide
 methanesulfonate 676500-93-9P, 6-[4-[[[3-Ethylpentylamino)methyl]-
 2-methoxyphenoxy]nicotinamide methanesulfonate 676500-94-0P,
 6-[2-Methoxy-4-[[[2-(morpholin-4-yl)ethyl]amino)methyl]phenoxy]nicotinamid
 e methanesulfonate 676500-96-2P, 6-[2-Methoxy-4-[[[2-
 (thiomorpholin-4-yl)ethyl]amino)methyl]phenoxy]nicotinamide

methanesulfonate 676500-98-4P, 6-[2-Methoxy-4-[[[3-(morpholin-4-yl)propyl]amino]methyl]phenoxy]nicotinamide methanesulfonate 676501-04-5P, 5-[2-Fluoro-4-[[[2-(2-fluorophenyl)ethyl]amino]methyl]phenoxy]pyridine-2-carboxamide 676501-05-6P, 5-[2-Fluoro-4-[[[4-methylpentylamino]methyl]phenoxy]pyridine-2-carboxamide 676501-06-7P, 5-[4-[[[3,3-Dimethylbutylamino]methyl]-2-fluorophenoxy]pyridine-2-carboxamide 676501-08-9P, 5-[4-[[[3-Ethylpentylamino]methyl]-2-fluorophenoxy]pyridine-2-carboxamide 676501-09-0P, 5-[4-[[[2-Cyclopentylethylamino]methyl]-2-fluorophenoxy]pyridine-2-carboxamide 676501-10-3P, 5-[2-Fluoro-4-[[[2-(thiomorpholin-4-yl)ethyl]amino]methyl]phenoxy]pyridine-2-carboxamide 676501-22-7P, 6-[4-[[[2-(2-Fluorophenyl)ethyl]amino]methyl]-2-methoxyphenoxy]nicotinamide methanesulfonate 676501-26-1P, 6-[2-Fluoro-4-[[[2-(tetrahydropyran-4-yl)ethyl]amino]methyl]phenoxy]nicotinamide methanesulfonate 676501-29-4P, 6-[4-[[[2-(4-Fluorophenyl)ethyl]amino]methyl]-2-methoxyphenoxy]nicotinamide methanesulfonate 676501-31-8P, 5-[2-Methoxy-4-[[[2-(tetrahydropyran-4-yl)ethyl]amino]methyl]phenoxy]pyridine-2-carboxamide methanesulfonate 676501-40-9P, N-Methyl-6-[4-[[[phenethylamino]methyl]phenoxy]nicotinamide 676501-58-9P, N-Ethyl-6-[4-[[[phenethylamino]methyl]phenoxy]nicotinamide 676501-60-3P, N-Isopropyl-6-[4-[[[phenethylamino]methyl]phenoxy]nicotinamide 676501-61-4P, N-Methyl-6-[4-[[[3-methylbutylamino]methyl]phenoxy]nicotinamide 676501-63-6P, N-Isopropyl-6-[4-[[[3-methylbutylamino]methyl]phenoxy]nicotinamide 676501-82-9P, 6-[2-Methyl-4-[[[3-methylbutylamino]methyl]phenoxy]nicotinamide methanesulfonate 676501-83-0P, 6-[4-[[[2-(Tetrahydropyran-4-yl)ethyl]amino]methyl]phenoxy]nicotinamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(opioid receptor antagonist; preparation of (aryloxy)nicotinamides and analogs as opioid receptor antagonist for treatment of obesity and related conditions)


RN 676494-28-3 HCAPLUS

CN 3-Pyridinecarboxamide, 6-[2-methyl-4-[[[2-(phenylethyl)amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676494-30-7 HCAPLUS

CN 3-Pyridinecarboxamide, 6-[2-fluoro-4-[[[2-(phenylethyl)amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676494-32-9 HCAPLUS


CN 3-Pyridinecarboxamide, 6-[2-ethoxy-4-[[[2-(phenylethyl)amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676494-34-1 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[2-chloro-4-[[2-phenylethyl]amino]methyl]phenoxy
]- (CA INDEX NAME)




RN 676494-36-3 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[3-chloro-4-[[2-phenylethyl]amino]methyl]phenoxy
]- (CA INDEX NAME)




RN 676494-40-9 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[2-chloro-4-[[3-methylbutyl]amino]methyl]phenoxy
]- (CA INDEX NAME)



RN 676494-41-0 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[2-ethoxy-4-[[3-methylbutyl]amino]methyl]phenoxy
]- (CA INDEX NAME)




RN 676494-42-1 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[2-cyclopentylethyl]amino]methyl]-2-methylphenoxy]- (CA INDEX NAME)




RN 676494-43-2 HCAPLUS

CN 3-Pyridinecarboxamide, 6-[4-[[2-(2-cyclopentylethyl)amino]methyl]-2-fluorophenoxy]- (CA INDEX NAME)




RN 676494-44-3 HCAPLUS

CN 3-Pyridinecarboxamide, 6-[2-chloro-4-[[2-(2-cyclopentylethyl)amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676494-45-4 HCAPLUS

CN 3-Pyridinecarboxamide, 6-[4-[[2-(2-cyclopentylethyl)amino]methyl]-2-ethoxyphenoxy]- (CA INDEX NAME)




RN 676494-46-5 HCAPLUS

CN 3-Pyridinecarboxamide, 6-[2-methyl-4-[[2-(2-thienyl)ethyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676494-47-6 HCAPLUS


CN 3-Pyridinecarboxamide, 6-[4-[[2-(3-fluorophenyl)ethyl]amino]methyl]-2-methylphenoxy]- (CA INDEX NAME)




RN 676494-48-7 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[2-methyl-4-[[[2-(2-methylphenyl)ethyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676494-50-1 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[[2-(3-chlorophenyl)ethyl]amino]methyl]-2-methylphenoxy]- (CA INDEX NAME)




RN 676494-51-2 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[(butylamino)methyl]-2-methylphenoxy]- (CA INDEX NAME)




RN 676494-53-4 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[2-methyl-4-[[methyl(2-phenylethyl)amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676494-69-2 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[[2-(phenylmethyl)amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676494-71-6 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[(2-propenylamino)methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 676494-72-7 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[[(4-methoxyphenyl)methyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676494-73-8 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[[3-(trifluoromethyl)phenyl]methyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676494-74-9 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[[2-(2-thienyl)ethyl]amino]methyl]phenoxy]- (CA INDEX NAME)



RN 676494-75-0 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[[(3-fluorophenyl)methyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676494-76-1 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[[(2-furanylmethyl)amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676494-77-2 HCAPLUS

CN 3-Pyridinecarboxamide, 6-[4-[[[2-(3-fluorophenyl)ethyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676494-78-3 HCAPLUS

CN 3-Pyridinecarboxamide, 6-[4-[[[4-(trifluoromethoxy)phenyl]methyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676494-79-4 HCAPLUS

CN 3-Pyridinecarboxamide, 6-[4-[[[2-(phenylethyl)amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676494-80-7 HCAPLUS

CN 3-Pyridinecarboxamide, 6-[4-[[[2-(3-chlorophenyl)ethyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676494-81-8 HCAPLUS

CN 3-Pyridinecarboxamide, 6-[4-[[[2-[4-(aminosulfonyl)phenyl]ethyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676494-82-9 HCAPLUS


CN 3-Pyridinecarboxamide, 6-[4-[[[3-(phenylpropyl)amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676494-83-0 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[3,3-diphenylpropyl]amino]methyl]phenoxy]-
 (CA INDEX NAME)




RN 676494-84-1 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[3,3-dimethylbutyl]amino]methyl]phenoxy]-
 (CA INDEX NAME)




RN 676494-85-2 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[2-(2-methoxyphenyl)ethyl]amino]methyl]phenoxy]-
 (CA INDEX NAME)



RN 676494-86-3 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[2-(phenylamino)ethyl]amino]methyl]phenoxy]-
 (CA INDEX NAME)




RN 676494-87-4 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[2-(phenylpropyl)amino]methyl]phenoxy]-
 (CA INDEX NAME)




RN 676494-88-5 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[2-(2-pyridinyl)ethyl]amino]methyl]phenoxy]-
 (CA INDEX NAME)


(CA INDEX NAME)




RN 676494-89-6 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[[2-(2-chlorophenyl)ethyl]amino]methyl]phenoxy]-
 (CA INDEX NAME)




RN 676494-90-9 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[[2-(3-pyridinyl)ethyl]amino]methyl]phenoxy]-
 (CA INDEX NAME)




RN 676494-91-0 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[[2-(2-diphenylethyl)amino]methyl]phenoxy]-
 (CA INDEX NAME)




RN 676494-92-1 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[[2-(2-cyclohexylethyl)amino]methyl]phenoxy]-
 (CA INDEX NAME)




RN 676494-93-2 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[[2-(2-cyclohexylethyl)amino]methyl]phenoxy]-
 (CA INDEX NAME)




RN 676494-94-3 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[2-(methylthio)ethyl]amino]methyl]phenoxy] -
 (CA INDEX NAME)




RN 676494-95-4 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[6-hydroxyhexyl]amino]methyl]phenoxy] - (CA
 INDEX NAME)




RN 676494-96-5 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[2-(dimethylamino)ethyl]amino]methyl]phenoxy
] - (CA INDEX NAME)




RN 676494-97-6 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[decylamino]methyl]phenoxy] - (CA INDEX NAME)



RN 676494-98-7 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[2-ethylhexyl]amino]methyl]phenoxy] - (CA
 INDEX NAME)




RN 676494-99-8 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[[(tetrahydro-2-furanyl)methyl]amino]methyl]p
 henoxyl] - (CA INDEX NAME)




RN 676495-00-4 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[[2-(1-pyrrolidinyl)ethyl]amino]methyl]phenoxy]- (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 676495-01-5 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676495-02-6 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[[2-(1H-imidazol-4-yl)ethyl]amino]methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 676495-03-7 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[[3-(2-methyl-1-piperidinyl)propyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676495-04-8 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[[2-[bis(1-methylethyl)amino]ethyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676495-05-9 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[[2-(1-cyclohexen-1-yl)ethyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676495-06-0 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[(pentylamino)methyl]phenoxy]- (CA INDEX NAME)



RN 676495-26-4 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[[2-(3,4-dichlorophenyl)ethyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676495-27-5 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[[2-(2-ethoxyphenyl)ethyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676495-28-6 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[[2-(2-methylphenyl)ethyl]amino]methyl]phenoxy]- (CA INDEX NAME)


y] - (CA INDEX NAME)




RN 676495-29-7 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[2-(2-phenoxymethyl)ethyl]amino]methyl]phenoxy] - (CA INDEX NAME)



RN 676495-39-9 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[2,5-dimethyl-4-[[2-(2-phenoxymethyl)ethyl]amino]methyl]phenoxy] - (CA INDEX NAME)




RN 676495-41-3 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[2-ethoxy-4-[[2-(2-thienyl)ethyl]amino]methyl]phenoxy] - (CA INDEX NAME)



RN 676495-42-4 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[2-ethoxy-4-[[3-methylbutyl]amino]methyl]phenoxy] - (CA INDEX NAME)

CM 1


CRN 676494-41-0
 CMF C20 H27 N3 O3




CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 676495-43-5 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[(butylamino)methyl]-2-ethoxyphenoxy]- (CA INDEX NAME)



RN 676495-44-6 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[2-(cyclopentylethyl)amino]methyl]-2-ethoxyphenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 676494-45-4
 CMF C22 H29 N3 O3




CM 2

CRN 75-75-2
 CMF C H4 O3 S



RN 676495-67-3 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[[(3R)-1-(phenylmethyl)-3-pyrrolidinyl]amino]methyl]phenoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 676496-12-1 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[[[2-(4-methylcyclohexyl)ethyl]amino]methyl]phenoxy]-, monomethanesulfonate (9CI)
 (CA INDEX NAME)


CM 1

CRN 676496-11-0
 CMF C23 H31 N3 O3




CM 2


CRN 75-75-2
 CMF C H4 O3 S




RN 676496-22-3 HCAPLUS
 CN 3-Pyridinecarboximidamide, 6-[4-[[[2-(phenylethyl)amino]methyl]phenoxy]-
 (CA INDEX NAME)



RN 676496-28-9 HCAPLUS
 CN 2-Pyridinecarboxamide, 5-[4-[[[2-(phenylethyl)amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676496-41-6 HCAPLUS
 CN 3-Pyridinecarboximidamide, N-methyl-6-[4-[[[2-(phenylethyl)amino]methyl]phenoxy]- (CA INDEX NAME)



RN 676496-45-0 HCAPLUS
 CN 2-Pyridinecarboxamide, 5-[4-[[[2-(4-fluorophenyl)ethyl]amino]methyl]phenox

y] - (CA INDEX NAME)




RN 676496-50-7 HCAPLUS

CN 2-Pyridinecarboxamide, 5-[4-[[[(3-methylbutyl)amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 676496-49-4


CMF C18 H23 N3 O2



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 676496-52-9 HCAPLUS

CN 2-Pyridinecarboxamide, 5-[2-methyl-4-[[[(3-methylbutyl)amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 676496-51-8


CMF C19 H25 N3 O2



CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 676496-55-2 HCAPLUS
 CN 2-Pyridinecarboxamide, 5-[2-methoxy-4-[[[(3-methylbutyl)amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 676496-54-1
 CMF C19 H25 N3 O3



CM 2


CRN 75-75-2
 CMF C H4 O3 S



RN 676496-58-5 HCAPLUS
 CN 2-Pyridinecarboxamide, 5-[4-[[[2-[3-(trifluoromethyl)phenyl]ethyl]amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 676496-57-4
 CMF C22 H20 F3 N3 O2



CM 2


CRN 75-75-2
 CMF C H4 O3 S




RN 676496-60-9 HCAPLUS
 CN 2-Pyridinecarboxamide, 5-[4-[[[2-(2-thienyl)ethyl]amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 676496-59-6
 CMF C19 H19 N3 O2 S




CM 2

CRN 75-75-2
CMF C H4 O3 SRN 676496-62-1 HCAPLUS
CN 2-Pyridinecarboxamide, 5-[2-methyl-4-[[[2-(2-thienyl)ethyl]amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 676496-61-0
CMF C20 H21 N3 O2 S

CM 2


CRN 75-75-2
CMF C H4 O3 SRN 676496-64-3 HCAPLUS
CN 2-Pyridinecarboxamide, 5-[2-methoxy-4-[[[2-(2-thienyl)ethyl]amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 676496-63-2
CMF C20 H21 N3 O3 S




CM 2

CRN 75-75-2
CMF C H4 O3 SRN 676496-68-7 HCAPLUS
CN 2-Pyridinecarboxamide, 5-[4-[[[(2-cyclopentylethyl)amino]methyl]-2-methylphenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 676496-67-6
CMF C21 H27 N3 O2

CM 2


CRN 75-75-2
CMF C H4 O3 SRN 676496-70-1 HCAPLUS
CN 2-Pyridinecarboxamide, 5-[4-[[[(2-cyclopentylethyl)amino]methyl]-2-methoxyphenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 676496-69-8
CMF C21 H27 N3 O3




CM 2


CRN 75-75-2
CMF C H4 O3 S

RN 676496-72-3 HCAPLUS
CN 2-Pyridinecarboxamide, 5-[4-[[{(benzo[b]thien-3-ylmethyl)amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM .1


CRN 676496-71-2
CMF C22 H19 N3 O2 S

CM 2


CRN 75-75-2
CMF C H4 O3 S

RN 676496-74-5 HCAPLUS
CN 2-Pyridinecarboxamide, 5-[4-[[[2-(4-methoxyphenyl)ethyl]amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 676496-73-4
CMF C22 H23 N3 O3

CM 2


CRN 75-75-2
CMF C H4 O3 S

RN 676496-76-7 HCAPLUS
 CN 2-Pyridinecarboxamide, 5-[4-[[[2-(3-fluorophenyl)ethyl]amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 676496-75-6
CMF C21 H20 F N3 O2

CM .2

CRN 75-75-2
CMF C H4 O3 S


RN 676496-78-9 HCAPLUS
 CN 2-Pyridinecarboxamide, 5-[4-[[[2-(2-fluorophenyl)ethyl]amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 676496-77-8
CMF C21 H20 F N3 O2

CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 676496-80-3 HCAPLUS
 CN 2-Pyridinecarboxamide, 5-[2-fluoro-4-[[[3-methylbutyl]amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 676496-79-0
 CMF C18 H22 F N3 O2




CM 2


CRN 75-75-2
 CMF C H4 O3 S




RN 676496-88-1 HCAPLUS
 CN 2-Pyridinecarboxamide, 5-[2-fluoro-4-[(pentylamino)methyl]phenoxy]- (CA INDEX NAME)



RN 676496-89-2 HCAPLUS
 CN 2-Pyridinecarboxamide, 5-[2-fluoro-4-[[[2-(2-thienyl)ethyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676496-90-5 HCAPLUS
 CN 2-Pyridinecarboxamide, 5-[2-fluoro-4-[[[2-(3-pyridinyl)ethyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676496-91-6 HCAPLUS

CN 2-Pyridinecarboxamide, 5-[2-fluoro-4-[[[2-(3-methylphenyl)ethyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676496-92-7 HCAPLUS

CN 2-Pyridinecarboxamide, 5-[2-fluoro-4-[[[2-(4-fluorophenyl)ethyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676496-93-8 HCAPLUS

CN 2-Pyridinecarboxamide, 5-[2-chloro-4-[[[2-(3-methylbutyl)amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676496-96-1 HCAPLUS

CN 2-Pyridinecarboxamide, 5-[2-chloro-4-[[[2-(2-thienyl)ethyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676496-97-2 HCAPLUS

CN 2-Pyridinecarboxamide, 5-[2-chloro-4-[[[2-(2-thienyl)ethyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676496-98-3 HCAPLUS

CN 2-Pyridinecarboxamide, 5-[2-chloro-4-[[[2-(3-pyridinyl)ethyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676496-99-4 HCAPLUS

CN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[[[2-(3-methylbutyl)amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676497-01-1 HCAPLUS

CN 2-Pyridinecarboxamide, 5-[2-fluoro-4-[[[2-(tetrahydro-2H-pyran-4-yl)ethyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676497-02-2 HCAPLUS

CN 2-Pyridinecarboxamide, 5-[2-fluoro-4-[[[2-(2-methylphenyl)ethyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676497-03-3 HCAPLUS

CN 2-Pyridinecarboxamide, 5-[4-[[[2-(2-naphthalenyl)ethyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676497-04-4 HCAPLUS
 CN 2-Pyridinecarboxamide, 5-[4-[[2-(1-naphthalenyl)ethyl]amino]methyl]phenoxy]- (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 676497-05-5 HCAPLUS
 CN 2-Pyridinecarboxamide, 5-[4-[[2-(benzo[b]thien-3-ylethyl)amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676497-06-6 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[(pentylamino)methyl]phenoxy]- (CA INDEX NAME)




RN 676497-07-7 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[[[2-(2-thienyl)ethyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676497-08-8 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[[[2-(2-methylphenyl)ethyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676497-09-9 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[[[2-(3-methylphenyl)ethyl]amino]methyl]phenoxy]- (CA INDEX NAME)



RN 676497-10-2 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[[(3,3-dimethylbutyl)amino]methyl]-2-methoxyphenoxy]- (CA INDEX NAME)




RN 676497-11-3 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[[[2-(3-pyridinyl)ethyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676497-12-4 HCAPLUS

CN 3-Pyridinecarboxamide, 6-[4-[(butylamino)methyl]-2-methoxyphenoxy]- (CA INDEX NAME)




RN 676497-14-6 HCAPLUS

CN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[[[2-(4-morpholinyl)ethyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676497-15-7 HCAPLUS

CN 3-Pyridinecarboxamide, 6-[4-[[[2-ethylbutyl]amino]methyl]-2-methoxyphenoxy]- (CA INDEX NAME)



RN 676497-18-0 HCAPLUS

CN 3-Pyridinecarboxamide, 6-[4-[(hexylamino)methyl]-2-methoxyphenoxy]- (CA INDEX NAME)




RN 676497-20-4 HCAPLUS

CN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[[[4-methylpentyl]amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 676497-19-1
CMF C20 H27 N3 O3



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 676497-22-6 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[[[2-(4-methylphenyl)ethyl]amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 676497-21-5
CMF C23 H25 N3 O3



CM 2


CRN 75-75-2
CMF C H4 O3 S







RN 676497-30-6 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[[[2-(tetrahydro-2H-pyran-4-yl)ethyl]amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 676497-13-5
CMF C21 H27 N3 O4




CM 2

CRN 75-75-2
CMF C H4 O3 SRN 676497-67-9 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[2-fluoro-4-[[[(3-methylbutyl)pentylamino)methyl]phenoxy]- (CA INDEX NAME)RN 676497-68-0 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[2-fluoro-4-[[[(3-methylbutyl)propylamino)methyl]phenoxy]- (CA INDEX NAME)RN 676497-69-1 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[[bis(3-methylbutyl)amino)methyl]-2-fluorophenoxy]- (CA INDEX NAME)RN 676497-86-2 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[2-chloro-4-[[[(3,3-dimethylbutyl)amino)methyl]phenoxy]- (CA INDEX NAME)





RN 676497-87-3 HCAPLUS

CN 3-Pyridinecarboxamide, 6-[2-chloro-4-[[[2-(2-thienyl)ethyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676499-89-1 HCAPLUS

CN 3-Pyridinecarboxamide, 6-[4-[[[(cyclopropylmethyl)(3-methylbutyl)amino]methyl]-2-fluorophenoxy]- (CA INDEX NAME)




RN 676499-90-4 HCAPLUS

CN 3-Pyridinecarboxamide, 6-[4-[[[(cyclohexylmethyl)(3-methylbutyl)amino]methyl]-2-fluorophenoxy]- (CA INDEX NAME)




RN 676499-91-5 HCAPLUS

CN 3-Pyridinecarboxamide, 6-[4-[[[ethyl 2-(3-pyridinyl)ethyl]amino]methyl]-2-fluorophenoxy]- (CA INDEX NAME)




RN 676499-92-6 HCAPLUS


CN 3-Pyridinecarboxamide, 6-[4-[[[(cyclopropylmethyl)amino]methyl]-2-fluorophenoxy]- (CA INDEX NAME)




RN 676499-93-7 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[cyclohexylmethyl]amino]methyl]-2-fluorophenoxy]- (CA INDEX NAME)




RN 676499-94-8 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[cycloheptylamino]methyl]-2-fluorophenoxy]- (CA INDEX NAME)




RN 676499-95-9 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[cyclooctylamino]methyl]-2-fluorophenoxy]- (CA INDEX NAME)



RN 676499-96-0 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[1,1-dimethylethyl]amino]methyl]-2-fluorophenoxy]- (CA INDEX NAME)




RN 676499-97-1 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[2-fluoro-4-[[2-furanylmethyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676499-98-2 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[2-fluoro-4-[[[(1S)-1-phenylethyl]amino]methyl]phenoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 676499-99-3 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[2-fluoro-4-[[[(1R)-1-phenylethyl]amino]methyl]phenoxy]- (CA INDEX NAME)


Absolute stereochemistry.




RN 676500-00-8 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[(ethylamino)methyl]-2-fluorophenoxy]- (CA INDEX NAME)




RN 676500-01-9 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[2-fluoro-4-[(propylamino)methyl]phenoxy]- (CA INDEX NAME)




RN 676500-02-0 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[2-fluoro-4-[(hexylamino)methyl]phenoxy]- (CA INDEX NAME)



RN 676500-03-1 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[2-fluoro-4-[(2-methylpropyl)amino]methyl]phenoxy]-
 (CA INDEX NAME)




RN 676500-25-7 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[(3-methylbutyl)amino]methyl]phenoxy]-,
 monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 676500-38-2 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[2,3-difluoro-4-[(pentylamino)methyl]phenoxy]-
 (CA INDEX NAME)



RN 676500-42-8 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[(3,3-dimethylbutyl)amino]methyl]-2-fluoro-6-methoxyphenoxy]- (CA INDEX NAME)




RN 676500-45-1 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[(3,3-dimethylbutyl)amino]methyl]-2,6-difluorophenoxy]- (CA INDEX NAME)




RN 676500-48-4 HCAPLUS

CN 3-Pyridinecarboxamide, 6-[2,6-difluoro-4-[[3-(3-methylbutyl)amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676500-49-5 HCAPLUS

CN 3-Pyridinecarboxamide, 6-[2,3,6-trifluoro-4-[[3-(3-methylbutyl)amino]methyl]phenoxy]- (CA INDEX NAME)



RN 676500-53-1 HCAPLUS

CN 3-Pyridinecarboxamide, 6-[3-[[2-(2-cyclohexylethyl)amino]methyl]-2-methylphenoxy]- (CA INDEX NAME)




RN 676500-64-4 HCAPLUS

CN 3-Pyridinecarboxamide, 6-[4-[[[2-(2,4-difluorophenyl)ethyl]amino]methyl]-2-methoxyphenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 676500-63-3

CMF C22 H21 F2 N3 O3




CM 2


CRN 75-75-2
CMF C H4 O3 S

RN 676500-73-5 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[(propylamino)methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 676500-72-4
CMF C17 H21 N3 O3

CM 2

CRN 75-75-2
CMF C H4 O3 S


RN 676500-75-7 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[[2-methylpropyl]amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 676500-74-6
CMF C18 H23 N3 O3

CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 676500-77-9 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[[(2,2-dimethylpropyl)amino]methyl]-2-methoxyphenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 676500-76-8
 CMF C19 H25 N3 O3



CM 2


CRN 75-75-2
 CMF C H4 O3 S



RN 676500-79-1 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[[[(tetrahydro-2H-pyran-4-yl)methyl]amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 676500-78-0
 CMF C20 H25 N3 O4



CM 2


CRN 75-75-2
 CMF C H4 O3 S



RN 676500-81-5 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[(heptylamino)methyl]-2-methoxyphenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 676500-80-4
 CMF C21 H29 N3 O3



CM 2


CRN 75-75-2
 CMF C H4 O3 S



RN 676500-83-7 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[[[2-(4-pyridinyl)ethyl]amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 676500-82-6
 CMF C21 H22 N4 O3



CM 2


CRN 75-75-2
 CMF C H4 O3 S



RN 676500-85-9 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[[[3-methoxypropyl]amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 676500-84-8
CMF C18 H23 N3 O4



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 676500-87-1 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[[[3-(ethoxypropyl)amino]methyl]-2-methoxyphenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 676500-86-0
CMF C19 H25 N3 O4



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 676500-89-3 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[[[3-(1-methylethoxy)propyl]amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 676500-88-2
CMF C20 H27 N3 O4



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 676500-91-7 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[[[2-(1-methylethoxy)ethyl]amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 676500-90-6
CMF C19 H25 N3 O4



CM 2


CRN 75-75-2
CMF C H4 O3 S




RN 676500-93-9 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[[[3-ethylpentyl]amino]methyl]-2-methoxyphenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 676500-92-8
CMF C21 H29 N3 O3




CM 2


CRN 75-75-2
CMF C H4 O3 S

RN 676500-94-0 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[[[2-(4-morpholinyl)ethyl]amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 676497-14-6
CMF C20 H26 N4 O4


CM 2

CRN 75-75-2
CMF C H4 O3 S

RN 676500-96-2 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[[[2-(4-thiomorpholinyl)ethyl]amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 676500-95-1
CMF C20 H26 N4 O3 S



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 676500-98-4 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[2-methoxy-4-[[[3-(4-morpholinyl)propyl]amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 676500-97-3
CMF C21 H28 N4 O4




CM 2

CRN 75-75-2
CMF C H4 O3 S




RN 676501-04-5 HCAPLUS
CN 2-Pyridinecarboxamide, 5-[2-fluoro-4-[[[2-(2-fluorophenyl)ethyl]amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676501-05-6 HCAPLUS


CN 2-Pyridinecarboxamide, 5-[2-fluoro-4-[[[4-methylpentyl)amino]methyl]phenoxy]-
y]- (CA INDEX NAME)




RN 676501-06-7 HCAPLUS
CN 2-Pyridinecarboxamide, 5-[4-[[[3,3-dimethylbutyl)amino]methyl]-2-fluorophenoxy]- (CA INDEX NAME)




RN 676501-08-9 HCAPLUS
CN 2-Pyridinecarboxamide, 5-[4-[[[3-ethylpentyl)amino]methyl]-2-fluorophenoxy]- (CA INDEX NAME)



RN 676501-09-0 HCAPLUS
CN 2-Pyridinecarboxamide, 5-[4-[[[2-cyclopentylethyl)amino]methyl]-2-fluorophenoxy]- (CA INDEX NAME)



RN 676501-10-3 HCAPLUS
CN 2-Pyridinecarboxamide, 5-[2-fluoro-4-[[[2-(4-thiomorpholinyl)ethyl)amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676501-22-7 HCAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[[[2-(2-fluorophenyl)ethyl)amino]methyl]-2-

methoxyphenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 676497-17-9


CMF C22 H22 F N3 O3



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 676501-26-1 HCAPLUS

CN 3-Pyridinecarboxamide, 6-[2-fluoro-4-[[[2-(tetrahydro-2H-pyran-4-yl)ethyl]amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 676501-25-0


CMF C20 H24 F N3 O3



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 676501-29-4 HCAPLUS

CN 3-Pyridinecarboxamide, 6-[4-[[[2-(4-fluorophenyl)ethyl]amino]methyl]-2-methoxyphenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 676497-16-8

CMF C22 H22 F N3 O3




CM 2


CRN 75-75-2
CMF C H4 O3 S

RN 676501-31-8 HCAPLUS
CN 2-Pyridinecarboxamide, 5-[2-methoxy-4-[[[2-(tetrahydro-2H-pyran-4-yl)ethyl]amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 676501-30-7
CMF C21 H27 N3 O4


CM 2

CRN 75-75-2
CMF C H4 O3 S


RN 676501-40-9 HCAPLUS
CN 3-Pyridinecarboxamide, N-methyl-6-[4-[[[2-(phenylethyl)amino]methyl]phenoxy]]- (CA INDEX NAME)




RN 676501-58-9 HCAPLUS
CN 3-Pyridinecarboxamide, N-ethyl-6-[4-[[[2-(phenylethyl)amino]methyl]phenoxy]]- (CA INDEX NAME)




RN 676501-60-3 HCAPLUS
 CN 3-Pyridinecarboxamide, N-(1-methylethyl)-6-[4-[(2-phenylethyl)amino]methyl]phenoxy]- (CA INDEX NAME)



RN 676501-61-4 HCAPLUS
 CN 3-Pyridinecarboxamide, N-methyl-6-[4-[(3-methylbutyl)amino]methyl]phenoxy]- (CA INDEX NAME)




RN 676501-63-6 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[(3-methylbutyl)amino]methyl]phenoxy]-N-(1-methylethyl)- (CA INDEX NAME)



RN 676501-82-9 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[2-methyl-4-[(3-methylbutyl)amino]methyl]phenoxy]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 676494-38-5
 CMF C19 H25 N3 O2




CM 2

CRN 75-75-2
 CMF C H4 O3 S



RN 676501-83-0 HCAPLUS
 CN 3-Pyridinecarboxamide, 6-[4-[[[2-(tetrahydro-2H-pyran-4-yl)ethyl]amino]methyl]phenoxy]- (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 10:24:33 ON 17 OCT 2007)

FILE 'HCAPLUS' ENTERED AT 10:24:55 ON 17 OCT 2007

L1 1 US20070112036/PN

FILE 'REGISTRY' ENTERED AT 10:25:27 ON 17 OCT 2007

FILE 'HCAPLUS' ENTERED AT 10:25:27 ON 17 OCT 2007

L2 TRA L1 1- RN : 40 TERMS

FILE 'REGISTRY' ENTERED AT 10:25:27 ON 17 OCT 2007

L3 40 SEA L2
 L4 17 L3 AND NC5/ES
 L5 4 L3 AND NOC3-C6/ES
 L6 21 L4-5
 L7 2 L3 AND N2C3-C6/ES
 L8 23 L6-7
 L9 SEL RN 1 3-10 12-13 15-19 L8
 16 E1-16 AND L8

FILE 'HCAPLUS' ENTERED AT 11:24:44 ON 17 OCT 2007

L10 1 L9

FILE 'REGISTRY' ENTERED AT 11:24:59 ON 17 OCT 2007

L11 1 859505-35-4

FILE 'HCAPLUS' ENTERED AT 11:25:11 ON 17 OCT 2007

L12 1 L11

FILE 'REGISTRY' ENTERED AT 11:25:49 ON 17 OCT 2007

L13 STR
 L14 STR L13
 L15 4 L14
 L16 2025948 46.150.18/RID AND (NC5 OR NOC3-C6 OR N2C3-C6)/ES
 L17 15 L14 SAM SUB=L16
 L18 STR L14
 L19 3 L18 SAM SUB=L16
 L20 STR L18
 L21 2 L20 SAM SUB=L16
 L22 679 L20 FULL SUB=L16
 SAV TEM J178C14B/A L22
 L23 9 L22 AND (C20H27N3O2 OR C18H24N4O2 OR C18H24N4O OR C20H24N4O OR
 L24 10 L22 AND (C22H30N4O OR C21H28N4O OR C19H23N5O OR C18H22N6O OR C2
 L25 4 L22 AND (C22H20FN3O2 OR C21H25N3O3 OR C19H24N4O OR C18H22N2O3)
 L26 23 L23-25
 L27 20 L26 NOT C5/ES
 L28 0 L22 AND SE/ELS
 L29 656 L22 NOT L26
 L30 8 L22 AND NOC3-C6/ES
 L31 4 L29 AND NOC3-C6/ES

L32 58 L29 AND N2C3-C6/ES
L33 1 PYRIDINE/CN
L34 596 L29 AND 46.156.30/RID
L35 STR L20
L36 16 L35 SAM SUB=L22
L37 276 L35 FULL SUB=L22
L38 276 L37 AND 46.156.30/RID
L39 258 L38 NOT L26

FILE 'HCAPLUS' ENTERED AT 12:55:08 ON 17 OCT 2007

L40 18 L39
L41 7 L40 AND (PD<=20031222 OR AD<=20031222 OR PRD<=20031222)
SEL HIT RN

FILE 'REGISTRY' ENTERED AT 12:56:22 ON 17 OCT 2007

L42 217 E17-233
L43 11 L42 AND (C18H20F3N3O2 OR C20H26FN3O2 OR C18H21F2N3O2 OR C19H25N
SEL RN 1 3-11
L44 10 E234-243 AND L43

FILE 'HCAPLUS' ENTERED AT 13:14:44 ON 17 OCT 2007

L45 1 L44 AND L41
L46 1 L10,L12

=>